XML 48 R40.htm IDEA: XBRL DOCUMENT v3.25.1
Collaborations - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Jul. 07, 2020
May 09, 2019
Mar. 31, 2025
Mar. 31, 2024
Sep. 30, 2023
Dec. 31, 2024
Dec. 31, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Cost reimbursement payment received     $ 900        
Unbilled accounts receivable     20,000        
Research and development     $ 80,255 $ 48,819      
Remaining research term of collaboration     6 months        
Revenue     $ 22,100 10,287      
Deferred Revenue     3,700        
Milestone Two [Member]              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenue recognized recorded in deferred revenue     19,800        
Unconstrained Consideration     20,000       $ 55,000
Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenue Recognized     75,000        
Minimum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenue Recognized     71,300        
Sanofi Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Upfront payment $ 150,000            
Collaboration agreement transaction price 150,000            
Revenue recognized recorded in deferred revenue     22,100 10,300      
Unsatisfied performance obligation     11,500     $ 13,600  
Revenue           3,100  
Unconstrained Consideration     20,000        
Sanofi Agreement | Milestone One [Member]              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Collaboration revenue recognised         $ 40,000    
Sanofi Agreement | Milestone Two [Member]              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Collaboration revenue recognised         $ 15,000    
Sanofi Agreement | Collaboration Target 1              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Collaboration agreement transaction price 120,000            
Sanofi Agreement | Collaboration Target 2              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Collaboration agreement transaction price 30,000            
Sanofi Agreement | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Development milestone payments 1,480,000            
Commercial Milestone Payments 700,000            
Sanofi Agreement | Minimum | IRAK4 Program              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Development milestone payments 1,000,000            
Commercial Milestone Payments $ 400,000            
Vertex Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Unsatisfied performance obligation     $ 0 $ 0   $ 0  
Initial research term of collaboration   4 years          
Extended research term of collaboration   1 year          
Vertex Agreement | Series B-1 Preferred Stock              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Collaboration agreement transaction price   $ 55,900          
Non refundable upfront payment received   $ 50,000          
Stock Issued During Period, Shares, New Issues   3,059,695          
Stock issued price per share   $ 6.54          
Preferred stock premium   $ 5,900          
Vertex Agreement | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Eligible to receive payments including development, regulatory and commercial milestones   $ 170,000